General description
INN
Atezolizumab
Medicine type
Biological agent
EML status history
Application rejected in 2019
(TRS
1021)
for
Other specified malignant neoplasms of bronchus or lung
Added in 2025
(TRS
1064)
for
Other specified malignant neoplasms of bronchus or lung
Application rejected in 2025
(TRS
1064)
for
Adenocarcinoma of stomach
Application rejected in 2025
(TRS
1064)
for
Hepatocellular carcinoma of liver
Therapeutic equivalent for
Wikipedia
DrugBank
Recommendations
Section
Immunomodulators
- Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion
- Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion